The Mechanism and Pathways of Dopamine and Dopamine Agonists in Prolactinomas [PDF]
Frontiers in Endocrinology, 2019 Dopamine agonists such as bromocriptine and cabergoline are the predominant treatment drugs for prolactinoma by inhibiting prolactin secretion and shrinking tumor size.
Xiaoshuang Liu +6 more
doaj +7 more sources
Dopamine Agonists for Pituitary Adenomas [PDF]
Frontiers in Endocrinology, 2018 Dopamine agonists (DA) are well established as first-line therapy for prolactinomas. These tumors express high levels of dopamine 2 receptors (D2R), leading to the strong efficacy of DA in reducing tumor size and hormonal secretion. Other pituitary tumor
Odelia Cooper, Yona Greenman
doaj +6 more sources
Dopamine Agonists and Pathologic Behaviors [PDF]
Parkinson's Disease, 2012 The dopamine agonists ropinirole and pramipexole exhibit highly specific affinity for the cerebral dopamine D3 receptor. Use of these medications in Parkinson’s disease has been complicated by the emergence of pathologic behavioral patterns such as ...
Brendan J. Kelley +2 more
doaj +4 more sources
Metabolic effects of prolactin and the role of dopamine agonists: A review. [PDF]
Front Endocrinol (Lausanne), 2022 Prolactin is a polypeptide hormone that is well known for its role in reproductive physiology. Recent studies highlight its role in neurohormonal appetite regulation and metabolism. Elevated prolactin levels are widely associated with worsening metabolic
Kirsch P, Kunadia J, Shah S, Agrawal N.
europepmc +2 more sources
Dopamine agonists for preventing ovarian hyperstimulation syndrome. [PDF]
Cochrane Database Syst Rev, 2021 BACKGROUND Ovarian hyperstimulation syndrome (OHSS) is a potentially serious complication of ovarian stimulation in assisted reproduction technology (ART).
Tang H +4 more
europepmc +2 more sources
Clinical Aspects and Management of Levodopa-Induced Dyskinesia [PDF]
Parkinson's Disease, 2012 In Parkinson's disease, one of the most troublesome dilemmas is the treatment of levodopa-induced dyskinesia. After a few years, chronic treatment with levodopa is associated with the development of dyskinesias.
Nicola Tambasco +7 more
doaj +4 more sources
Dopamine agonists in Parkinson’s disease: Impact of D1-like or D2-like dopamine receptor subtype selectivity and avenues for future treatment [PDF]
Clinical Parkinsonism & Related Disorders, 2023 Dopamine agonists (DAs) have demonstrated efficacy for the treatment of Parkinson’s disease (PD) but are limited by adverse effects (AEs). DAs can vary considerably in their receptor subtype selectivity and affinity, chemical composition, receptor ...
Stuart H. Isaacson +4 more
doaj +2 more sources
Time until Need for Levodopa among New Users of Dopamine Agonists or MAO-B Inhibitors [PDF]
Parkinson's Disease, 2021 Objective. To investigate the use of dopamine agonists and monoamine oxidase type B (MAO-B) inhibitors in the Norwegian population, between 1 July 2006 and 31 December 2016.
Caroline D. Binde +2 more
doaj +2 more sources
Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis. [PDF]
Eur J Clin Pharmacol, 2020 To investigate the comparative effectiveness of dopamine agonists and monoamine oxidase type-B (MAO-B) inhibitors available for treatment of Parkinson’s disease.
Binde CD +4 more
europepmc +2 more sources
Macroprolactinoma with secondary resistance to dopamine agonists: a case report and review of the literature [PDF]
Journal of Medical Case Reports, 2023 Background Resistance to dopamine agonists is not uncommonly seen in prolactinomas. However, development of resistance to dopamine agonists after an initial period of robust treatment response is rare, and only 39 cases have been reported in the past ...
Eng-Loon Tng +2 more
doaj +2 more sources